Hims & Hers Health (HIMS) stock falls after reporting lower Q2 revenues. Analysts caution about near-term challenges, ...

A Massachusetts biotech working on a class of medicines called circular RNA therapeutics beat out companies from around the ...

As consumer interest in metabolic health, gut support and clean-label products accelerates, dietary fiber, like carob, ...

Claire Reed, from Aberdeen in Scotland, was prescribed Mounjaro in March after she was left 'fed up' of not fitting into her ...

Linda Yaccarino has a new job in a vastly different industry weeks after her exit as CEO of X, Elon Musk 's social discourse ...

GLP-1RAs were associated with lower risk for major adverse cardiovascular and cerebrovascular events in MGUS with type 2 diabetes.

Linda Yaccarino is taking the top job at eMed Population Health, a telehealth startup focused on GLP-1 weight loss drugs, ...

Novo Nordisk (NYSE: NVO) stock is testing the patience of buy-and-hold investors. Over the last five years, NVO stock is up more than 200%. However, in the last year, it’s down over 61% and more than ...

Hims & Hers delivered strong Q2 growth, driven by compounded GLP-1 offerings, but faces uncertainty as regulatory and supply ...

Aetna’s multi-year margin recovery is a top priority, and CVS is making progress through organizational realignment, ...

MCK's Q1 results are expected to reflect strong prescription volume growth from GLP-1 demand, but lower margins may weigh on profitability.

Inspire Medical Systems crashed Tuesday after the maker of implantable sleep apnea devices called out GLP-1 drugs for ...